Drug Trial Radar · NCT04089579
hCT-MSC in Children With Autism Spectrum Disorder
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Oct 12, 2020
Primary completion
May 2, 2023
Study completion Feb 1, 2024
Sponsor
- Lead sponsor
- Joanne Kurtzberg, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Marcus Foundation; Cryo-Cell International
- First posted
- Sep 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder (ASD).
Conditions
- Autism
- Autism Spectrum Disorder
Interventions
Cord Tissue Mesenchymal Stromal CellsBiological
Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
Placebo InfusionOther
Placebo comparative infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change on the Average Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales (VABS-3)Time frame: Baseline, 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.